EUCTR2007-007177-23-BE进行中（未招募）1 期
A randomized phase II of bevacizumab, capecitabine and radiation therapy with or without oxaliplatin in the preoperative treatment of locally advanced rectal cancer - Axe Beam
.Z. Gasthuisberg0 个研究点开始时间: 2008年9月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient is at least 18 years of age.
- •Patient’s body weight is = 120 kg.
- •Histologically proven and evaluable (according to RECIST criteria) adenocarcinoma of the rectum (tumor = 12 cm from the anal verge).
- •Patient is considered locally advanced by MRI; the following are eligible:
- •Tumor beyond mesorectal fascia (T4)
- •Tumor = 2 mm from mesorectal fascia
- •T3 tumor < 5 cm from anal verge
- •All radiology studies must be performed within 28 days prior to randomization.
- •WHO PS = 2
- •Adequate bone marrow, hepatic and renal function (assessed within 14 days prior to study entry)
- •INR = 1.5 .
- •Ability to swallow tablets.
- •Presence of adequate contraception in fertile patients. Adequate methods of contraception are: intra-uterine device, hormonal contraception, condom use with spermicide.
- •Written informed consent must be given according to ICH/GCP and national/local regulations
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Evidence of distant metastases.
- •Prior chemotherapy or radiotherapy for rectal cancer.
- •Pregnant or breastfeeding women.
- •Presence of peripheral neuropathy > grade 1, according to CTCAE v3.0
- •Presence of significant impairment of intestinal resorption (e.g. chronic diarrhea, inflammatory bowel disease).
- •History or presence of allergy or any other adverse reaction to any of the study drugs or to any related compound, including hypersensitivity to chinese hamster ovary cell products or other recombinant human or humanised antibodies.
- •Known dihydropyrimidine dehydrogenase (DPD) deficiency.
- •History of arterial thrombo-embolic events, including transient ischemic attack (TIA), cerebro-vascular accident (CVA), and myocardial infarction within 6 months prior to randomisation. Presence of clinically significant peripheral artery disease or hemorrhagic events.
- •Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia not well controlled with medication or history of myocardial infarction within the last 12 months.
- •Presence of uncontrolled hypertension (defined as a systolic blood pressure more than 140 mmHg and diastolic blood pressure more than 90 mmHg). If the patient is unaware of his/her blood pressure and hypertension is detected, a cardiologic check-up prior to inclusion in this trial is mandatory.
- •Treatment with full dose of anticoagulants (coumarine or heparin). Patients with prophylactic dose of low molecular weight heparin are eligible.
- •Major surgical procedure or significant traumatic injury within 28 days before day 1 or patients in whom a surgical wound is not fully healed
- •Presence of other uncontrolled concomitant illness, including serious uncontrolled intercurrent infection.
- •Previous or concurrent malignancies at other sites with the exception of surgically cured or adequately treated carcinoma in-situ of the cervix and non-melanoma skin cancer.
- •Presence of organ allografts requiring immunosuppressive therapy.
- •Requirement for concurrent use of the antiviral agent sorivudine or chemically related analogues, such as brivudine. Patients must be off these drugs for 4 weeks before enrollment.
- •History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.
- •Administration of any investigational drug or agent/procedure, i.e. participation in another trial within 4 weeks before beginning treatment with study drug.
- •Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
研究者
相似试验
招募中
2 期
Phase II trial of capecitabine + bevacizumab as maintenance treatment after initial treatment with XELOX in previously untreated metastatic colorectal canceradvanced colorectal cancerJPRN-UMIN000006111SGCSG: Shimane Gastroenterological Cancer Study Group50
进行中（未招募）
1 期
A randomized phase II trial with bevacizumab, irinotecan and cerebral radiotherapy versus bevacizumab, temozolomide and cerebral radiotherapy as first line treatment for patients with glioblastoma multiformeEUCTR2008-001144-39-DKRigshospitalet60
已完成
2 期
A randomized Phase II Study of Bevacizumab in Combination with Docetaxel or S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer Previously Treated with Platinum based Chemotherapyon-Squamous Non-Small-Cell Lung CancerJPRN-UMIN000003533Hanshin Cancer Study Group90
已完成
2 期
A randomized Phase II Study of Bevacizumab in Combination with Docetaxel or S-1 as second line therapy in wild-type EGFR Patients with Non-Squamous Non-Small-Cell Lung Cancer. After failure to first line therapy, platinum doublet plus bevacizumab.on-Squamous Non-Small-Cell Lung CancerJPRN-UMIN000009602ung Oncology Group in Kyushu, Japan (LOGIK)60
进行中（未招募）
不适用
A clinical phase II trial to compare the efficacy of Bevacizumab monotherapy with standard chemotherapy (dacarbazine) in metastatic melanoma.Previously treated or untreated histologically confirmed metastatic and unresectable melanoma with radiological (RECIST), clinical or biochemical progressive disease.MedDRA version: 14.1Level: PTClassification code 10027480Term: Metastatic malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001020-35-NOHelse Bergen HF, Haukeland University Hospital